RTI uses cookies to offer you the best experience online. By and clicking “accept” on this website, you opt in and you agree to the use of cookies. If you would like to know more about how RTI uses cookies and how to manage them please view our Privacy Policy here. You can “opt out” or change your mind by visiting: http://optout.aboutads.info/. Click “accept” to agree.

Accept
  • Home
  • Impact
  • Publications
  • Cost-effectiveness model for neovascular age-related macular degeneration: Comparing early and late treatment with pegaptanib sodium based on visual acuity

Cost-effectiveness model for neovascular age-related macular degeneration: Comparing early and late treatment with pegaptanib sodium based on visual acuity

Javitt, JC., Zlateva, GP., Earnshaw, S., Pleil, AM., Graham, C., Brogan, A., Shah, SN., & Adamis, AR. (2008). Cost-effectiveness model for neovascular age-related macular degeneration: Comparing early and late treatment with pegaptanib sodium based on visual acuity. Value in Health, 11(4), 563-574.

Publications Info

To contact an RTI author, request a report, or for additional information about publications by our experts, send us your request.

Recent Publications

Article

Estimating regionalized planning costs of green infrastructure and low-impact development stormwater management practices
OCCASIONAL PAPER

Perceived, experienced, and internalized cancer stigma
CONFERENCE PROCEEDING

2021 National Institute of Justice Forensic Science Research and Development Symposium
Article

A latent class analysis of prevention approaches used to reduce community-level prescription drug misuse in adolescents and young adults